Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
announced today that the company has been awarded a significant portion
of the UNICEF human papillomavirus (HPV) vaccine tender, and will
provide sustained supply of GARDASIL [Human Papillomavirus
Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant] to
GAVI-eligible countries. This agreement follows the GAVI Alliances
earlier announcement that HPV vaccines would be included in its
portfolio for the first time.
Language:
English
Contact HTML:
MerckMedia:Pamela Eisele, 908-423-5042orImraan Munshi, 215-652-0059orInvestors:Carol Ferguson, 908-423-4465orJustin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more